Skip to main content

How is Stemchymal® performing in Clinical Trials? [INFOGRAPHIC]

By Zara Puckrin, BSc
Mesenchymal stem cells Cells under fluorescent microscope

Stemchymal®[1] is an allogenic stem cell therapeutic derived from the adipose tissue of healthy donors. Mesenchymal stem cells (MSCs) are isolated from the adipose tissue using a propriety cell processing system developed by Steminent Biotherapeutics[2].  The purified MSCs are then administered to patients via Intravenous (IV) infusion.

Scientist in stem cell clinical lab

REPROCELL offers comprehensive customised laboratory services for clinical research.

 Clinical laboratory services

Stemchymal cell therapy for SCA3

Currently, Stemchymal® is being trailed for the treatment of Spinocerebellar Ataxia 3 (SCA3) a condition characterized by progressive cerebellar ataxia. So far, the treatment has been deemed safe for IV administration. You can discover the main findings from the phase I and phase II trials in our infographic below.

Infographic Stemchymal Progress So far

Stemchymal phase I/II clinical trials 

In this infographic we have summarized the main findings from the Phase I/II clinical trials of Stemchymal®. We have also provided information on the disease this therapeutic aims to treat, and a timeline of how the drug is progressing clinically in different countries. Inquire now to find out more about our clinical capabilities → 

References

  1. What is Stemchymal® - Steminent Biotherapeutics
  2. About Steminent - Steminent Biotherapeutics 
  3. Tang et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neuro 57:4 (2000)
  4. Tsai et al. Treatment of Spinocerebellar Ataxia 3 with Mesenchymal Stem Cell treatment Stemchymal. Cell Trans 26 (2017)

Subscribe to receive updates from REPROCELL

Upcoming Events

Conferences and meetings we will be attending, and webinars hosted by us.

North East Life Science (UK) 2024

21 March / Newcastle upon Tyne, UK

AACR Annual Meeting 2024

7-10 April / San Diego, CA, USA
Booth #3950

IBD Innovate Conference 2024

9-10 April / Cambridge, MA, USA

International Conference on Cancer & Oncology Research

15-16 April / London, UK
REPROCELL/Bioserve booth